Fig. 1: LOXO-RAS-20001 Trial Schema. | Nature Communications

Fig. 1: LOXO-RAS-20001 Trial Schema.

From: Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study

Fig. 1: LOXO-RAS-20001 Trial Schema.The alternative text for this image may have been generated using AI.

Phase 1a included dose escalation and backfill cohorts, while Phase 1b included exploratory monotherapy expansion cohorts in select populations. a Includes solid tumors that are not NSCLC, CRC, or Pancreatic cancer. Abbreviations: BID twice a day, CRC colorectal cancer, NSCLC non-small cell lung cancer.

Back to article page